While the latest guidelines recommend SGLT2 inhibitors and GLP1-RA for adults with T2D and established CVD, [126, 127] an analysis of out-of-pocket costs in the USA found that, compared to the lowest quartile, individuals with the highest quartile of out-of-pocket costs were ~13% and ~20% less inclined to start GLP1-RA or SGLT2 inhibitor intervention, respectively [128]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.